Sequencing Strategies After Frontline Intensification in EGFR-Mutant NSCLC

Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, explore how prior exposure to chemotherapy influences second-line treatment decisions. They emphasize the importance of repeat biopsy, both tissue and liquid, to identify resistance mechanisms, including small cell transformation. The discussion also highlights how clinicians balance molecular findings with clinical tempo when selecting subsequent therapies.